Gene · 4070
TACSTD2: tumor associated calcium signal transducer 2
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. TACSTD2: tumor associated calcium signal transducer 2. Genes, record 4070. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/4070
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P09758 | Tumor-associated calcium signal transducer 2 | 323 | 7 | Ensembl, GeneID, HGNC |
Source UniProt
Patents124
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| WO 2026219249 A1 | 2026-10-22 | 35 | P09758 | Espacenet |
| WO 2026219939 A1 | 2026-10-22 | 74 | P09758 | Espacenet |
| US 12662549 B2 | 2026-06-23 | 39 | P09758 | Espacenet |
| EP 4754143 A1 | 2026-06-10 | 86 | P09758 | Espacenet |
| JP 2026516605 A | 2026-05-26 | 39 | P09758 | Espacenet |
| JP 2026515744 A | 2026-05-19 | 370 | P09758 | Espacenet |
| JP 2026515434 A | 2026-05-18 | 73 | P09758 | Espacenet |
| JP 2026514790 A | 2026-05-13 | 38 | P09758 | Espacenet |
| JP 2026513240 A | 2026-04-23 | 1 | P09758 | Espacenet |
| EP 4688866 A1 | 2026-02-11 | 39 | P09758 | Espacenet |
1 to 10 of 124
See all 124 patentsDrugs2
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
Trials156
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07582887 | SACITUZUMAB GOVITECAN | ClinicalTrials.gov | ||
| NCT07582887 | DATOPOTAMAB DERUXTECAN | ClinicalTrials.gov | ||
| NCT07561463 | SACITUZUMAB GOVITECAN | PHASE2 | ClinicalTrials.gov | |
| NCT07535437 | DATOPOTAMAB DERUXTECAN | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07504588 | SACITUZUMAB GOVITECAN | PHASE2 | ClinicalTrials.gov | |
| NCT07492914 | SACITUZUMAB GOVITECAN | PHASE2 | ClinicalTrials.gov | |
| NCT07438600 | SACITUZUMAB GOVITECAN | PHASE2 | ClinicalTrials.gov | |
| NCT07393555 | SACITUZUMAB GOVITECAN | PHASE2 | ClinicalTrials.gov | |
| NCT07368543 | SACITUZUMAB GOVITECAN | PHASE2 | ClinicalTrials.gov | |
| NCT07367178 | SACITUZUMAB GOVITECAN | PHASE2 | ClinicalTrials.gov |
1 to 10 of 156
See all 156 trialsNIH grants1,195
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | TACSTD2 papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 22 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 20 | 2025 |
| P30CA016042 | Cancer Center Support Grant | 14 | 2025 |
| P30CA014520 | UW Comprehensive Cancer Center Support | 13 | 2025 |
| P30CA016359 | Cancer Center Support Grant | 12 | 2025 |
| UL1TR001863 | Yale Clinical and Translational Science Award | 12 | 2025 |
| P50CA097186 | The Pacific Northwest Prostate Cancer SPORE | 11 | 2025 |
| R01DK101332 | Induction and Evolution of Metaplasia in the Stomach | 8 | 2025 |
| I01BX000930 | Oxyntic Atrophy and Novel Gastric Lineages. | 7 | 2025 |
| T32CA009056 | Tumor Cell Biology Training Program | 7 | 2025 |
1 to 10 of 1,195Source NIH's project files
See all 1,195 nih grantsPapers3,230
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Sacituzumab govitecan in metastatic breast cancer: a systematic review and meta-analysis of its clinical benefit and safety. | Front Med (Lausanne) | 2026 | 42827466 | PubTator, text mining | PubMed |
| Biomarker-Driven Treatments for Ovarian Cancer: Moving Beyond HRD? | Int J Womens Health | 2026 | 42824309 | PubTator, text mining | PubMed |
| Antibody-drug conjugates in breast cancer: redefining targeted therapy. | J Clin Invest | 2026 | 42820303 | PubTator, text mining | PubMed |
| Quantitative Systems Pharmacology Model for TROP-2 Targeted Antibody-Drug Conjugate in Triple-Negative Breast Cancer. | bioRxiv | 2026 | 42818000 | PubTator, text mining | PubMed |
| Systemic and intracranial activity of antibody-drug conjugates in patients with non-small cell lung cancer and brain metastases: A systematic review and meta-analysis. | Lung Cancer | 2026 | 42815252 | PubTator, text mining | PubMed |
| Time to Rethink Pathology Reporting in Adenoid Cystic Carcinoma. | Head Neck | 2026 | 42811719 | PubTator, text mining | PubMed |
| A phase I, first-in-human dose-escalation and triple-negative breast cancer dose-expansion study of a TROP2-ADC F0024 (FDA018). | Eur J Cancer | 2026 | 42810148 | PubTator, text mining | PubMed |
| Dermatologic adverse events associated with Sacituzumab Govitecan: an international retrospective study from the EADV Task Force "Dermatology for Cancer Patients" and pharmacovigilance analysis. | Breast Cancer Res Treat | 2026 | 42804021 | PubTator, text mining | PubMed |
| TROP2-Targeting Chimeras (TRTACs) for Tumor Cell-Selective Membrane Protein Degradation and Enhanced Drug Delivery. | Adv Sci (Weinh) | 2026 | 42801692 | PubTator, text mining | PubMed |
| Antibody-Drug Conjugates in Lung Cancer: Promise, Progress, and Persistent Challenges. | Curr Issues Mol Biol | 2026 | 42793224 | PubTator, text mining | PubMed |
1 to 10 of 3,230
See all 3,230 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/4070
GET https://conductscience.org/api/genes/v1/4070/patents?page=2